Lipoprotein (a) in patients with psoriasis: Associations with lipid profiles and disease severity

International Journal of Dermatology

Volumn 48, Issue 4, 2009, Pages 379-387

  Pietrzak, Aldona ^a,b,c   Kadzielewski, Jacek ^a,b,c   Janowski, Konrad ^a,b,c   Roliński, Jacek ^a,b,c   Krasowska, Dorota ^a,b,c   Chodorowska, Grazyna ^a,b,c   Paszkowski, Tomasz ^a,b,c   Kapeć, Ewa ^a,b,c   Jastrzbska, Iwona ^a,b,c   Tabarkiewicz, Jacek ^a,b,c   Lotti, Torello ^a,b,c  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b JOHN PAUL II CATHOLIC UNIVERSITY OF LUBLIN   (Poland)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COLORIMETRY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; HUMAN; HYPERLIPIDEMIA; LIPID ANALYSIS; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MALE; PATHOPHYSIOLOGY; PRECIPITATION; PSORIASIS; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CHOLESTEROL, VLDL; HUMANS; HYPERLIPIDEMIAS; LIPIDS; LIPOPROTEIN(A); MALE; MIDDLE AGED; PSORIASIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TRIGLYCERIDES; YOUNG ADULT;

EID: 63549116815     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2009.03994.x     Document Type: Article

References (87)

1. Berg K. A new serum type system in man: The Lp system. Acta Pathol Microbiol Scand 1963; 59: 369-382.
2. Utermann G. The mysteries of lipoprotein(a). Science 1989; 246: 904-910.
3. Gancarz A. Lipoproteina(a) jako biochemiczny marker miażdżycy naczyń wieńcowych. Lek Wojsk 1996; 1-2: 69-72.
4. Seçkin D, Tokgözolu L, Akkaya S. Are lipoprotein profile and lipoprotein(a) levels altered in men with psoriasis? J Am Acad Dermatol 1994; 31: 443-449.
5. Gaubatz JW, Heideman C, Gotto AM Jr, et al. Human plasma lipoprotein[a]. Structural properties. J Biol Chem 1983; 258: 4582-4589.
6. Utermann G, Weber W. Protein composition of Lp(a) lipoprotein from human plasma. FEBS Lett 1983; 154: 357-361.
7. Scanu AM. Lipoprotein(a): A genetically determined cardiovascular pathogen in search of a function. J Lab Clin Med 1990; 116: 142-146.
8. Edelstein C, Italia JA, Scanu AM. Polymorphonuclear cells isolated from human peripheral blood cleave lipoprotein(a) and apolipoprotein(a) at multiple interkringle sites via the enzyme elastase. Generation of mini-lp(a) particles and apo(a) fragments. J Biol Chem 1997; 272: 11, 079-11, 087.
9. Ballantyne CM, Chan L, Guevara J Jr, et al. Recent advances in lipoprotein and atherosclerosis research at Baylor College of Medicine. Apolipoprotein B, lipoprotein(a), and transplantation arteriopathy. Text Heart Inst J 1994; 21: 48-55.
10. Gabel B, Yao Z, McLeod RS, et al. Carboxyl-terminal truncation of apolipoprotein B-100 inhibits lipoprotein(a) particle formation. FEBS Lett 1994; 350: 77-81.
11. McCormick SPA, Linton MF, Hobbs HH, et al. Expression of human apolipoprotein B90 in transgenic mice: Demonstration that apolipoprotein B90 lacks the structural requirements to form lipoprotein(a). J Biol Chem 1994; 269: 24, 284-24, 289.
12. Brunner C, Kraft HG, Utermann G, et al. Cys4057 of apolipoprotein(a) is essential for lipoprotein(a) assembly. Proc Natl Acad Sci USA 1993; 90: 11,643-11,647.
13. Koschinsky ML, Cote GP, Gabel B, et al. Identification of the cysteine residue in apolipoprotein B-100. J Biol Chem 1993; 268: 19, 819-19, 825.
14. Sundell J, Laine H, Raitakari OT, et al. Increased lipoprotein(a) is associated with reduced myocardial vasoreactivity in young healthy men. Atherosclerosis 2005; 179: 185-191.
15. Loscalzo J. Lipoprotein(a): A unique risk factor for atherothrombotic disease. Atherosclerosis 1990; 10: 672-679.
16. Scanu AM, Fless GM. Lipoprotein(a): Heterogeneity and biological relevance. J Clin Invest 1990; 85: 1709-1715.
17. Scanu AM, Lawn RM, Berg K, Lipoprotein(a) and atherosclerosis. Ann Intern Med 1991; 115: 209-218.
18. Scanu AM, Scandiani L. Lipoprotein(a): Structure, biology, and clinical relevance. Adv Intern Med 1991; 36: 249-270.
19. Cybulska B, Szostal WBK, Kłosiewicz-Latoszek L. Makroskładniki. In: Masliński S, Ryzewski J, eds. Patofizjologia. Warsaw: Wydawnictwo Lekarskie PZWL, 2000.
20. Murawska-Ciałowicz E, Popławska A. Lipoproteina(a) -budowa, własciwosci, znaczenie fizjologiczne i patologiczne. Post Hig Med Dośw 2003; 57: 323-333.
21. Angles-Cano E. Overview on fibrinolysis: Plasminogen activation pathways on fibrin and cell surfaces. Chem Phys Lipids 1994; 67-68: 353-362.
22. Jialal I. Evolving lipoprotein risk factors: Lipoprotein(a) and oxidized low density lipoprotein. Clin Chem 1998; 44: 1827-1832.
23. Testa R, Marcovina SM. The rate of plasmin formation after in vitro clotting is inversely related to lipoprotein(a) plasma levels. Int J Clin Lab Res 1999; 29: 128-132.
24. Kural BV, Örem A, Çimşit G, et al. Evaluation of the atherogenic tendency of lipids and lipoprotein content and their relationships with oxidant-antioxidant system in patients with psoriasis. Clin Chim Acta 2003; 328: 71-82.
25. Kural BV, Örem A, Çimsit G, et al. Plasma homocysteine and its relationship with atherothrombotic markers in psoriatic patients. Clin Chim Acta 2003; 332: 23-30.
26. Vahlquist C, Michaëlsson G, Vessby B. Serum lipoproteins in middle-aged men with psoriasis. Acta Derm Venereol 1987; 67: 12-15.
27. Zołotuchina H. Native plasma treatment of children with psoriasis. Sov Med 1970; 33: 147-148.
28. Nesterenko GB, Kogon GKh, Ulanovskaya FD. Lipid metabolism in patients with changes in the osteoarticular apparatus in psoriasis. Vestn Dermatol Venereol 1971; 45: 31-34.
29. Dowzański SI, Graszkina IG, Suworow AP. Relationship between certain indicators of lipid metabolism in the skin and blood in psoriasis. Vestn Dermatol Venereol 1974; 48: 15-18.
30. Dowzański SI, Suworow AP. Metabolism pathology in psoriasis. Dermatol Monatsschr 1974; 160: 460-467.
31. Panfiłowa TS, Tananowa GV. Some indices of lipid metabolism in children suffering from psoriasis. Vestn Dermatol 1983; 6: 60-61.
32. Lurie WŁ, Korotki NG, Szafranowa GJ. Effect of hemosorption on the state of lipid metabolism in patients with psoriasis. Vestn Dermatol Venereol 1985; 59: 50-53.
33. Olisowa MO, Polyanskaja NP, Akimov VG. Study of lipoprotein blood spectrum in patients with disseminated psoriasis in the course of selective phototherapy. Vestn Dermatol 1985; 3: 10-13.
34. Imamura T, Takata I, Tominaga K, et al. [Serum apolipoprotein levels in psoriatic patients]. Nippon Hifuka Gakkai Zasshi 1990; 100: 1023-1028.
35. Uyanik BS, Ari Z, Onur E, Gunduz K, Tanulku S, Durkan K. Serum lipids and apolipoproteins in patients with psoriasis. Clin Chem Lab Med 2002; 40: 65-68.
36. Pietrzak A, Jastrzebska I, Krasowska D, et al. Serum pancreatic lipase [EC 3.1.1.3]activity, serum lipid profile and peripheral blood dendritic cell populations in normolipidemic males with psoriasis. J Mol Catal B Enzym 2006; 40: 144-154.
37. Simonetti O, Ferretti G, Salvi A, et al. Plasma lipid changes in psoriatic children. Dermatology 1992; 185: 96-100.
38. Örem A, Deger O, Çimşit G, et al. Plasma polymorphonuclear leukocyte elastase levels and its relation to disease activity in psoriasis. Clin Chim Acta 1997; 264: 49-56.
39. Rocha-Pereira P, Santos-Silva A, Rebelo I, et al. Dyslipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clin Chim Acta 2001; 303: 33-39.
40. Piskin S, Gurkok F, Ekuklu G, et al. Serum lipid levels in psoriasis. Yonsei Med J 2003; 44: 24-26.
41. Mallbris L, Akre O, Granath F, et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004; 19: 225-230.
42. Jones SM, Harris CP, Lloyd J, et al. Lipoproteins and their subfractions in psoriatic arthritis: Identification of an atherogenic profile with active joint disease. Ann Rheum Dis 2000; 59: 904-909.
43. Stinson J, O'Toole E, Cooke T, et al. Cholesterol and lipoprotein(a) levels in psoriasis. Ir Med J 1995; 88: 128-129.
44. Pietrzak A, Janowski K, Łopatyński J, et al. Psoriasis and heart. Something new under the sun. G Ital Dermatol Venereol 2006; 141: 457-463.
45. Pati U, Pati N. Lipoprotein(a), atherosclerosis, and apolipoprotein(a) gene polymorphism. Mol Genet Metab 2000; 71: 87-92.
46. Harris ED. Lipoprotein[a]: A predictor of atherosclerotic disease. Nutr Rev 1997; 55: 61-64.
47. Cassidy AE, Bielak LF, Kullo IJ, et al. Sex-specific associations of lipoprotein(a) with presence and quantity of coronary artery calcification in an asymptomatic population. Med Sci Monit 2004; 10: CR493-CR503.
48. Kostner GM, Avogaro P, Cazzolato G, et al. Lipoprotein Lp(a) and the risk for myocardial infarction. Atherosclerosis 1981; 38: 51-61.
49. Rhoads GG, Dahlen G, Berg K et al. Lp(a) lipoprotein as a risk factor for myocardial infarction. J Am Med Assoc 1986; 256: 2540-2544.
50. Genest J, McNamara JR, Ordovas JM. et al. Lipoprotein cholesterol, apolipoprotein A-I, B and lipoprotein(a) abnormalities in men with premature coronary disease. J Am Coll Cardiol 1992; 19: 792-802.
51. Genest J, Jenner JL, McNamara JR et al. Prevalence of lipoprotein(a) (Lp(a)) excess in coronary artery disease. Am J Cardiol 1991; 67: 1039-1045.
52. Rosengren A, Wilhemsen L, Eriksson E et al. Lipoprotein(a) and coronary heart disease: A prospective case-control study in a general population sample of middle aged men. Br Med J 1990; 301: 1248-1251.
53. Zenker G, Költringer P, BonéG, et al. Lipoprotein(a) as a strong indicator for cerebrovascular disease. Stroke 1986; 17: 942-945.
54. Çimsit G, Orem A, Deger O, et al. The variation of serum lipoprotein(a) level with disease activity in psoriasis. Br J Dermatol 1998; 138: 917-918.
55. Ludwig RJ, Herzog C, Rostock A, et al. Psoriasis: A possible risk factor for development of coronary artery calcification. Br J Dermatol 2007; 156: 271-276.
56. Reynoso-von Drateln C, Martínez-Abundis E, Balcázar-Muñoz BR, et al. Lipid profile, insulin secretion, and insulin sensitivity in psoriasis. J Am Acad Dermatol 2003; 48: 882-885.
57. Ucak S, Ekmekci TR, Basat O, et al. Comparison of various insulin sensitivity indices in psoriatic patients and their relationship with type of psoriasis. J Eur Acad Dermatol Venereol 2006; 20: 517-522.
58. Romano G, Moretti G, Di Benedetto A, et al. Skin lesions in diabetes mellitus: Prevalence and clinical correlations. Diabetes Res Clin Pract 1998; 39: 101-106.
59. Robinson D, Bala M, Wu Y, et al. Cardiovascular risk among US psoriasis patients: Evidence from two large healthcare databases. J Invest Dermatol 2006; 126 (Suppl. 4): 51.
60. Gelfand JM, Neimann AL, Shin DB, et al. The increased risk of myocardial infarction in patients with psoriasis. J Invest Dermatol 2006; 126 (Suppl. 4): 47.
61. Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis: A population-based study using the General Practice Research Database. J Invest Dermatol 2006; 126 (Suppl. 4): 48.
62. Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006; 55: 829-835.
63. Crown WH, Bresnahan BW, Orsini LS, et al. The burden of illness associated with psoriasis: Cost of treatment with systemic therapy and phototherapy in the US. Curr Med Res Opin 2004; 20: 1929-1936.
64. Pietrzak A, Lecewicz-Toruń B. Activity of serum lipase [EC 3.1.1.3]and the diversity of serum lipid profile in psoriasis. Med Sci Monit 2002; 8: 9-13.
65. Cicek H, Bayil S, Zer Y, et al. Comparison of lipoprotein(a) levels between elderly and middle-aged men with coronary artery disease. Ann NY Acad Sci 2007; 1100: 179-184.
66. Sattar N, Crompton P, Cherry L, et al. Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: A double-blind, placebo-controlled study. Arthritis Rheum 2007; 3: 831-839.
67. Peserico A, Zanetti G, Padovan S, et al. Relationship between body weight and blood pressure and some metabolic parameters in psoriatic patients. Br J Dermatol 1988; 118: 191-194.
68. Wilkinson DI. Lipid metabolism in psoriasis. In: Farber EM, Cox AJ, Jacobs PH, eds. Psoriasis. Proceedings of the International Symposium. Stanford, CA: Stanford University Press, 1971: 277-287.
69. Ansidei V, Binazzi M, Cantlemni A, et al. Phospholipid involvement in psoriatic epidermis. Ital J Biochem 1981; 30: 40-45.
70. Cho Y, Lew BL, Seong K, Kim NI. An inverse relationship between ceramide synthesis and clinical severity in patients with psoriasis. J Korean Med Sci 2004; 19: 859.
71. Osada M, Gniadecka M, Wulf HC. Near-infrared Fourier transform Raman spectroscopic analysis of proteins, water and lipids in intact normal stratum corneum and psoriasis scales. Exp Dermatol 2004; 13: 391-395.
72. Wohlrab J, Vollmann A, Wartewig S, et al. Noninvasive characterization of human stratum corneum of undiseased skin of patients with atopic dermatitis and psoriasis as studied by Fourier transform Raman spectroscopy. Biopolymers 2002; 62: 141-146.
73. Ishimaru H. Hautkranheiten und cholesterinaemiae. Acta Dermatol 1923; 1: 255.
74. Ena P, Madeddu P, Glorioso N, et al. High prevalence of cardiovascular diseases and enhanced activity of the renin-angiotensin system in psoriatic patients. Acta Cardiol 1985; 40: 199-205.
75. Barba A, Schena D, Ferrari S, et al. Osservazioni sul metabolismo lipidico in soggetti affetti da psoriasi. Dati preliminari. G Ital Dermatol Venereol 1987; 122: 85-89.
76. Ferretti G, Alleva R, Taus M, et al. Abnormalities of plasma lipoprotein composition and fluidity in psoriasis. Acta Derm Venereol 1994; 74: 171-175.
77. Offidani AM, Ferretti G, Taus M, et al. Lipoprotein peroxidation in adult psoriatic patients. Acta Derm Venereol Suppl (Stockh) 1994; 186: 38-40.
78. Seishima M, Mori S, Noma A. Serum lipid and apolipoprotein levels in patients with psoriasis. Br J Dermatol 1994; 130: 738-742.
79. Toruniowa B, Pietrzak A, Pietrzak B, et al. Activity of serum lipase EC 3.1.1.3 in psoriatic males. J Eur Acad Dermatol Venereol 1997; 8: 158-160.
80. Skoczyńska AH, Turczyn B, Barancewicz-Losek M, et al. High-density lipoprotein cholesterol in patients with psoriatic arthritis. J Eur Acad Dermatol Venereol 2003; 17: 362-363.
81. Mallbris L, Granath F, Hamsten A, et al. Psoriasis is associated with dyslipoproteinemia already at the onset of skin disease. Invest Dermatol 2005; 124: A49.
82. Pietrzak A, Lecewicz-Toruń B, Borzcki A. Postheparin serum lipolytic activity in psoriatic males. Med Sci Monit 2000; 6: 729-734.
83. Wilkinson DI. Psoriasis and dietary fat: The fatty acid composition of surface and scale (ether-soluble) lipids. Invest Dermatol 1966; 3: 185.
84. Melczer N, Bodzay J. Beitrage zur Atiologie und Pathogenese der Psoriasis vulgaris. [A contribution to the etiology and pathogenesis of psoriasis vulgaris]. Hautarzt 1958; 9: 351-355.
85. Ponec M, Havekes L, Kempenaar J, et al. Cultured human skin fibroblasts and keratinocytes: Differences in the regulation of cholesterol synthesis. J Invest Dermatol 1983; 81: 125-130.
86. Plotkin L, Mathof I, Squiquera HL, et al. Arachidonic acid released from epithelial cells by Malassezia furfur phospholipase A2: A potential pathophysiological mechanism. Mycologia 1998; 90: 163-169.
87. Camp RD. The variation of serum lipoprotein(a) level with disease activity in psoriasis. Br J Dermatol 1999; 140: 566-567.